Tarsus counsel granted options and RSUs

Wahl Bryan reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/09/2026 - 04:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Wahl Bryan reported acquisition or exercise transactions in this Form 4 filing.

Tarsus Pharmaceuticals General Counsel Bryan Wahl reported equity awards on March 5, 2026. He was granted stock options for 27,310 shares, with 25% vesting on March 5, 2027 and the remainder monthly over three years, and 17,161 restricted stock units vesting in four equal annual installments from March 15, 2027 to March 15, 2030, all subject to continuous service.

Insider Trade Summary

Grant/Award: 44,471 shares

Grant/Award 2 txns

Insider Wahl Bryan

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	27,310	$0.00	$0.00
Grant/Award	Restricted Stock Units	17,161	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 27,310 contracts (Direct); Restricted Stock Units — 17,161 contracts (Direct)

Footnotes (3)

1. F1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. F3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tarsus Pharmaceuticals (TARS) disclose in this Form 4 for Bryan Wahl?

Tarsus Pharmaceuticals reported that General Counsel Bryan Wahl received grants of stock options and restricted stock units. The options cover 27,310 shares and the RSUs cover 17,161 shares, both awarded on March 5, 2026, subject to specific multi‑year vesting schedules tied to continued service.

How many stock options were granted to Tarsus (TARS) General Counsel Bryan Wahl?

Bryan Wahl was granted stock options covering 27,310 shares of Tarsus Pharmaceuticals common stock. These options vest 25% on March 5, 2027, with the remaining shares vesting in equal monthly installments over the following three years, conditioned on his continuous service with the company.

What are the terms of the RSU grant to Tarsus (TARS) General Counsel Bryan Wahl?

Bryan Wahl received 17,161 restricted stock units, each representing a contingent right to one Tarsus common share. The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, provided he remains in continuous service through each vesting date.

When do Bryan Wahl’s Tarsus (TARS) stock options begin to vest?

The stock options granted to Bryan Wahl begin vesting on March 5, 2027. On that date, 25% of the 27,310 option shares vest, with the remaining option shares vesting in equal monthly installments over the subsequent three-year period, assuming continued service.

Over what period will Tarsus (TARS) RSUs for Bryan Wahl fully vest?

The 17,161 RSUs granted to Bryan Wahl will fully vest over approximately four years. They vest in four equal annual installments on March 15 of each year from 2027 through 2030, contingent upon his continued service with Tarsus Pharmaceuticals throughout that timeframe.

What does each RSU in the Tarsus (TARS) grant to Bryan Wahl represent?

Each restricted stock unit in Bryan Wahl’s grant represents a contingent right to receive one share of Tarsus Pharmaceuticals common stock. Actual share delivery depends on the RSUs vesting according to the stated schedule and his satisfying the continuous service requirement through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wahl Bryan

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$74.9	03/05/2026		A		27,310		(1)	03/04/2026	Common Stock	27,310	$0	27,310	D
Restricted Stock Units	(2)	03/05/2026		A		17,161		(3)	(3)	Common Stock	17,161	$0	17,161	D

Explanation of Responses:

1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.